Life Sciences Tools and Services

WuXi AppTec

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Acceleration of Chinese Innovative Drugs Internationalization and Wuxi Biologics' Exceeding Expectations in Q1 2026

BlackRock Increases Holding in Wuxi Biologics H Shares

HSBC Upgrades Wuxi Biologics Rating and Target Price

Goldman Sachs Analyst Gives Buy Rating to WuXi AppTec's H Shares

JPMorgan Raises Target Price for WuXi AppTec to HKD 172

Morgan Stanley Upgrades Rating on Wuxi Biologics Due to Strong Earnings

UBS Raises Goal Price and Earnings Forecast for Wuxi Biologics

WuXi AppTec Reiterates Its 2026 Revenue Guidance

WuXi AppTec Plans to Expand Capacity to Meet Order Demand

WuXi AppTec Reports Strong Core Business Growth in Q1

Company Continues to Focus on and Strengthen CRDMO Business Model

WuXi AppTec released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 12.44 B (forecast CNY 10.75 B), actual EPS CNY 1.58 (forecast CNY 1.36)

CLSA Raises Revenue and Profit Forecasts for Wuxi Biologics, Maintains Overweight Rating

Citi Raises Target Price on Wuxi Biologics to HKD 158.5

WuXi AppTec to Release FY2026 Q1 Earnings on April 27 After-Market BJT, Forecast Revenue CNY 10.75B, EPS CNY 1.36

WuXi AppTec Reports Record Operational Performance in 2025 Annual Report

600276

603259

02359

01276

G Sachs reports that China's healthcare sector has seen muted performance in 2026, with CRO/CDMO segments up 8% YTD. The broker favors visibility-led CDMO companies and selective pharmaceutical investments, focusing on upcoming clinical data. Key players include WUXI APPTEC, HENGRUI PHARMA, and INNOVENT BIO, with significant updates expected at ASCO and ADA meetings. The domestic hospital environment remains weak, prompting a preference for companies with overseas growth potential.

AASTOCKS News

Hengrui Pharma

WUXI APPTEC

HENGRUI PHARMA

Goldman Sachs

INNOVENT BIO

SKB BIO

MircroPort Medbot-B

EDGE MEDICAL-B

ANGELALIGN

GS Hldg R

G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market Bottoming

UBS reported that WUXI APPTEC announced the issuance of RMB6.78 billion one-year zero-coupon convertible bonds at 103.5% of the principal amount. The initial conversion price is HKD153 per share, a 17.6% premium over the previous closing price. UBS views this as slightly positive, reflecting management's confidence, and has set a target price of HKD171.2 with a Buy rating.

UBS Group AG

UBS: WUXI APPTEC  Zero-Coupon Convertible Bond Issuance Slightly Positive, Reflects Management Confidence

159892

159849

159837

WUXI APPTEC plans to issue RMB6.78 billion in zero-coupon convertible bonds due 2027, with an initial conversion price of HKD153 per H share. This represents a 17.6% premium over the previous closing price. The bonds may convert into approximately 51.147 million H shares, accounting for about 9.11% of the enlarged H share capital. Estimated net proceeds are around USD1.023 billion, with 90% allocated for global expansion and 10% for general corporate purposes.

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP CSI Pharmaceuticals ETF

First Trust NYSE Arca Biotech Index Fd

E Fund CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng Health Care ETF(QDII)

WUXI APPTEC  Plans to Issue RMB6.78B Convertible Bonds

02509

WXXWY

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

QYUNS-B

WuXi Biologics

WUXI BIO

TEDA BIOMEDICAL

WUXI XDC

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Citi's research report highlights ongoing improvements in China's healthcare sector, driven by innovative drugs and CDMOs. Key segments have stabilized, with sales of innovative drugs accelerating and record CXO order volumes. Upcoming catalysts include data releases and licensing momentum. Citi updated its Hong Kong Buy list, featuring top picks WUXI APPTEC, WUXI BIO, and ALI HEALTH, while noting sector-specific challenges have been largely absorbed by the market.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Universal 800 Health Care ETF

Citigroup

ALI HEALTH

CSPC PHARMA

ASCLETIS-B

Mindray

Aier

Yifeng Pharmacy

CR MEDICAL

Bloomage Biotech

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Citi: Fundamentals of China Healthcare Sector Continue to Improve; Top Picks WUXI APPTEC , WUXI BIO , ALI HEALTH

Goldman Sachs analyst Ziyi Chen has assigned a Buy rating to WuXi AppTec Co., Ltd. Class H (2359) with a price target of HK$169.40. The stock closed at HK$143.10. Chen, who focuses on the Healthcare sector, has an average return of 2.8% and a 45.68% success rate on recommendations. The analyst consensus for WuXi AppTec is Strong Buy, with a price target consensus of HK$157.63.

WuXi AppTec(603259.SH)

G Sachs: Continue to Favor Visibility-led CDMO, Closely Watch Early Signs of Market Bottoming

UBS: WUXI APPTEC Zero-Coupon Convertible Bond Issuance Slightly Positive, Reflects Management Confidence

WUXI APPTEC Plans to Issue RMB6.78B Convertible Bonds

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

Citi: Fundamentals of China Healthcare Sector Continue to Improve; Top Picks WUXI APPTEC , WUXI BIO , ALI HEALTH

WuXi AppTec Co., Ltd. Class H (2359) Receives a Buy from Goldman Sachs